Viveve Medical, Inc.

Equities

VIVE

US92852W5013

Advanced Medical Equipment & Technology

Market Closed - OTC Markets 10:57:20 2024-04-24 am EDT 5-day change 1st Jan Change
0.0003 USD 0.00% Intraday chart for Viveve Medical, Inc. +50.00% +50.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
InMode Ltd. acquired Intellectual Property Assets of Viveve Medical Inc. CI
Viveve Medical, Inc.(OTCPK:VIVE) dropped from S&P TMI Index CI
Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index CI
Sector Update: Health Care Stocks Finishing Near Intra-Day Lows MT
Sector Update: Health Care Stocks Sputtering in Tuesday Trading MT
Top Midday Decliners MT
Sector Update: Health Care MT
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday MT
Sector Update: Health Care MT
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures MT
Weak China GDP Data Weigh on Exchange-Traded Funds, Equity Futures Premarket Tuesday MT
Top Premarket Decliners MT
Viveve Medical Fails to Meet Primary Endpoint in Stress Urinary Incontinence Study; Unveils Cut in Workforce; Expects Delisting From Nasdaq MT
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence CI
Viveve Medical to Seek Strategic Alternatives CI
Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence CI
Transcript : Viveve Medical, Inc., Q3 2022 Earnings Call, Nov 10, 2022
Viveve Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Earnings Flash (VIVE) VIVEVE MEDICAL Posts Q3 Revenue $1.7M MT
Viveve Medical, Inc. announced that it has received $0.014675 million in funding CI
Viveve Medical, Inc. announced that it expects to receive $0.014675 million in funding CI
Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence CI
Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout CI
Transcript : Viveve Medical, Inc., Q2 2022 Earnings Call, Aug 11, 2022
Viveve Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chart Viveve Medical, Inc.
More charts
Viveve Medical, Inc. designs, develops, manufactures and markets a platform medical technology, Cryogen-cooled Monopolar RadioFrequency (CMRF). The Company’s CMRF technology is delivered through a radiofrequency generator, handpiece and treatment tip, which collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI). In the United States, the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis. The Viveve System is cleared for marketing in approximately 48 countries throughout the world, including North America, Asia Pacific, Europe, the Middle East and Latin America countries. The Company’s wholly owned subsidiaries include Viveve, Inc. and Viveve BV.
More about the company
  1. Stock Market
  2. Equities
  3. VIVE Stock
  4. News Viveve Medical, Inc.
  5. Alliance Global Adjusts Viveve Medical's Price Target to $5.25 From $10.75, Reiterates Buy Rating